Compare CBK & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBK | FHTX |
|---|---|---|
| Founded | 1975 | 2015 |
| Country | United States | United States |
| Employees | 298 | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.4M | 323.4M |
| IPO Year | N/A | 2020 |
| Metric | CBK | FHTX |
|---|---|---|
| Price | $33.43 | $5.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 93.5K | ★ 218.7K |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,909,000.00 |
| Revenue This Year | $11.67 | $8.89 |
| Revenue Next Year | $8.05 | $20.13 |
| P/E Ratio | $9.10 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $23.24 | $3.27 |
| 52 Week High | $33.83 | $6.95 |
| Indicator | CBK | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 74.59 | 75.33 |
| Support Level | $23.90 | $5.22 |
| Resistance Level | N/A | $5.84 |
| Average True Range (ATR) | 0.83 | 0.28 |
| MACD | 0.14 | 0.15 |
| Stochastic Oscillator | 87.35 | 97.10 |
Commercial Bancgroup Inc is a bank holding company. Through its subsidiary, it operates as a full-service community banking institution offering traditional consumer and commercial products and services to businesses and individuals in select markets in Kentucky, North Carolina, and Tennessee. In Tennessee, its service areas include the metropolitan statistical areas of Nashville Davidson, Murfreesboro, Franklin, Knoxville, and the Tri Cities region of Kingsport, Bristol, and Johnson City, as well as Claiborne County, Cocke County, Union County, Hamblen County, and their surrounding areas.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.